Technical Analysis for PCRX - Pacira Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 38.15 2.42% 0.90
PCRX closed up 2.42 percent on Friday, September 13, 2019, on 80 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical PCRX trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.42%
20 DMA Support Bullish 2.42%
Crossed Above 20 DMA Bullish 1.98%
Slingshot Bearish Bearish Swing Setup 3.84%
Bullish Engulfing Bullish 3.84%
MACD Bullish Signal Line Cross Bullish 3.84%
Pocket Pivot Bullish Swing Setup 3.84%
Oversold Stochastic Weakness 3.84%
New 52 Week Closing Low Bearish 6.98%

Older signals for PCRX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers worldwide. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company markets EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic, indicated for administration into the surgical site to produce postsurgical analgesia; and DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a cancer of the immune system. Its product pipeline comprise EXPAREL that has completed Phase II clinical trials for postsurgical analgesia-nerve block administration; DepoNSAID, which is in preclinical trials for the relief of acute pain; and DepoMethotrexate that is in preclinical trials for the treatment of rheumatoid arthritis and oncology, as well as Bupivacaine Liposome Injectable Suspension for veterinary postsurgical analgesia. Pacira Pharmaceuticals, Inc. has a development and commercialization agreement, and related supply agreement with Aratana Therapeutics, Inc. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.
Medicine Health Cancer Pharmaceutical Pain Surgery Pharmaceutical Products Pharmaceutical Industry In China Pharmacology Rheumatoid Arthritis Dosage Forms Piperidines Drug Delivery Technology Bupivacaine Liposome Surgical Site
Is PCRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 55.0
52 Week Low 34.64
Average Volume 537,204
200-Day Moving Average 41.1685
50-Day Moving Average 40.1064
20-Day Moving Average 37.1395
10-Day Moving Average 36.766
Average True Range 1.3387
ADX 23.05
+DI 23.371
-DI 24.0125
Chandelier Exit (Long, 3 ATRs ) 35.7239
Chandelier Exit (Short, 3 ATRs ) 38.6561
Upper Bollinger Band 38.9414
Lower Bollinger Band 35.3376
Percent B (%b) 0.78
BandWidth 9.703416
MACD Line -0.918
MACD Signal Line -1.2232
MACD Histogram 0.3052
Fundamentals Value
Market Cap 1.54 Billion
Num Shares 40.4 Million
EPS -1.72
Price-to-Earnings (P/E) Ratio -22.18
Price-to-Sales 4.67
Price-to-Book 5.03
PEG Ratio -3.43
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 39.91
Resistance 3 (R3) 39.78 39.07 39.62
Resistance 2 (R2) 39.07 38.62 39.13 39.52
Resistance 1 (R1) 38.61 38.34 38.84 38.74 39.42
Pivot Point 37.89 37.89 38.01 37.96 37.89
Support 1 (S1) 37.44 37.44 37.66 37.56 36.88
Support 2 (S2) 36.72 37.17 36.78 36.78
Support 3 (S3) 36.26 36.72 36.68
Support 4 (S4) 36.39